Heron Therapeutics (NASDAQ:HRTX) Posts Quarterly Earnings Results, Beats Expectations By $0.05 EPS

Heron Therapeutics (NASDAQ:HRTX) posted its quarterly earnings data on Thursday. The biotechnology company reported $0.02 earnings per share for the quarter, topping analysts’ consensus estimates of ($0.03) by $0.05, Zacks reports. The firm had revenue of $40.78 million during the quarter, compared to analysts’ expectations of $37.37 million. Heron Therapeutics updated its FY 2025 guidance to EPS.

Heron Therapeutics Stock Performance

NASDAQ HRTX traded up $0.25 on Friday, reaching $2.30. 2,143,244 shares of the stock traded hands, compared to its average volume of 1,630,635. The company has a market cap of $349.82 million, a price-to-earnings ratio of -12.80 and a beta of 1.60. Heron Therapeutics has a 12 month low of $1.04 and a 12 month high of $3.93. The company has a fifty day moving average price of $1.67 and a 200-day moving average price of $1.71.

Analyst Ratings Changes

A number of analysts have weighed in on HRTX shares. Needham & Company LLC reiterated a “buy” rating and issued a $4.00 target price on shares of Heron Therapeutics in a research note on Friday. StockNews.com cut shares of Heron Therapeutics from a “buy” rating to a “hold” rating in a report on Wednesday, January 29th.

Heron Therapeutics Company Profile

Heron Therapeutics, Inc, a commercial-stage biotechnology company, focuses on enhancing the lives of patients by developing and commercializing therapeutic that enhances medical care. The company's product candidates utilize its proprietary Biochronomer, a drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration.